Genzyme, Watson renal news

Genzyme filed suit in the U.S. District Court for the District of Maryland alleging that Watson infringed U.S. Patent No. 5,667,775 covering renal drug Renvela sevelamer carbonate. Watson has submitted an ANDA to FDA for a generic version of sevelamer carbonate. The ANDA contains a Paragraph IV notification that the '775 patent is invalid, unenforceable and/or will not be infringed by the approval or sale of Watson's generic. Genzyme is seeking to prevent the approval and sale of Watson's generic before the '775 patent expires on Sept. 16, 2014. ...